Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Merkel

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
International Journal of Cancer|October 9, 2020
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancerOsman Aksoy, Jan Pencik, Markus Hartenbach, et al.
Nature Medicine|October 16, 2012
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomasDaniela Laimer, Helmut Dolznig, Karoline Kollmann, et al.
Haematologica|May 25, 2019
High activation of STAT5A drives peripheral T-cell lymphoma and leukemiaBarbara Maurer, Harini Nivarthi, Bettina Wingelhofer, et al.
Nature Communications|July 23, 2015
STAT3 regulated ARF expression suppresses prostate cancer metastasisJan Pencik, Michaela Schlederer, Wolfgang Gruber, et al.
Nature Communications|October 27, 2015
Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasisJan Pencik, Michaela Schlederer, Wolfgang Gruber, et al.
Molecular Cancer|October 15, 2025
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growthAleksandra Fesiuk, Daniel Pölöske, Elvin D de Araujo, et al.
Blood|June 24, 2020
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphomaNina Prokoph, Nicola A Probst, Liam C Lee, et al.
Nature Communications|September 23, 2021
Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphomaHuan-Chang Liang, Mariantonia Costanza, Nicole Prutsch, et al.
EMBO Molecular Medicine|November 7, 2022
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphomaHelena Sorger, Saptaswa Dey, Pablo Augusto Vieyra-Garcia, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
International Journal of Cancer|October 9, 2020
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancerOsman Aksoy, Jan Pencik, Markus Hartenbach, et al.
Nature Medicine|October 16, 2012
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomasDaniela Laimer, Helmut Dolznig, Karoline Kollmann, et al.
Haematologica|May 25, 2019
High activation of STAT5A drives peripheral T-cell lymphoma and leukemiaBarbara Maurer, Harini Nivarthi, Bettina Wingelhofer, et al.
Nature Communications|July 23, 2015
STAT3 regulated ARF expression suppresses prostate cancer metastasisJan Pencik, Michaela Schlederer, Wolfgang Gruber, et al.
Nature Communications|October 27, 2015
Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasisJan Pencik, Michaela Schlederer, Wolfgang Gruber, et al.
Molecular Cancer|October 15, 2025
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growthAleksandra Fesiuk, Daniel Pölöske, Elvin D de Araujo, et al.
Blood|June 24, 2020
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphomaNina Prokoph, Nicola A Probst, Liam C Lee, et al.
Nature Communications|September 23, 2021
Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphomaHuan-Chang Liang, Mariantonia Costanza, Nicole Prutsch, et al.
EMBO Molecular Medicine|November 7, 2022
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphomaHelena Sorger, Saptaswa Dey, Pablo Augusto Vieyra-Garcia, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Pageof 6